Before a new cancer drug can be deemed effective, it must pass through several phases of clinical trials. These trials are typically divided into three main phases: - Phase I: Tests the drug’s safety and dosage. - Phase II: Focuses on effectiveness and further safety evaluation. - Phase III: Compares the new drug against the current standard treatment.
Patient enrollment often includes those who have not responded to existing therapies, making it crucial to demonstrate significant improvement over existing options.
